A Chimeric Plasmodium falciparum Merozoite Surface Protein Vaccine Induces High Titers of Parasite Growth Inhibitory Antibodies

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Infection and Immunity

• Publication date

  2013-07-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/IAI.00522-13PMID 23897613PMCID PMC3811772
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP142) administered intramuscularly with adjuvant system AS01

  2013cited by this paper
• A Field Trial to Assess a Blood-Stage Malaria Vaccine

  2013cited by this paper
• First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

  2013cited by this paper
• Phase 1 Study in Malaria Naïve Adults of BSAM2/Alhydrogel®+CPG 7909, a Blood Stage Vaccine against P. falciparum Malaria

  2012cited by this paper
• A review of malaria vaccine clinical projects based on the WHO rainbow table

  2012cited by this paper
• A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.

  2012cited by this paper
• Adjuvants for human vaccines.

  2012cited by this paper
• Evaluation of the Immunogenicity and Vaccine Potential of Recombinant Plasmodium falciparum Merozoite Surface Protein 8

  2012cited by this paper
• Evidence of purifying selection on merozoite surface protein 8 (MSP8) and 10 (MSP10) in Plasmodium spp.

  2012cited by this paper
• Use of defined TLR ligands as adjuvants within human vaccines

  2011cited by this paper
• A Research Agenda for Malaria Eradication: Vaccines

  2011cited by this paper
• First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.

  2011cited by this paper
• A field trial to assess a blood-stage malaria vaccine.

  2011cited by this paper
• T Cell Epitope Regions of the P. falciparum MSP1-33 Critically Influence Immune Responses and In Vitro Efficacy of MSP1-42 Vaccines

  2011cited by this paper
• Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.

  2010cited by this paper
• Blood stage vaccines for Plasmodium falciparum

  2010cited by this paper
• Phase 1 Trial of the Plasmodium falciparum Blood Stage Vaccine MSP142-C1/Alhydrogel with and without CPG 7909 in Malaria Naïve Adults

  2010cited by this paper
• Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.

  2010cited by this paper
• Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya

  2009cited by this paper
• A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali.

  2009cited by this paper
• Growth-Inhibitory Antibodies Are Not Necessary for Protective Immunity to Malaria Infection

  2009cited by this paper
• A Potent Malaria Transmission Blocking Vaccine Based on Codon Harmonized Full Length Pfs48/45 Expressed in Escherichia coli

  2009cited by this paper
• Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A

  2009cited by this paper
• The Immune Epitope Database 2.0

  2009cited by this paper
• Ex Vivo Cytokine and Memory T Cell Responses to the 42-kDa Fragment of Plasmodium falciparum Merozoite Surface Protein-1 in Vaccinated Volunteers1

  2008cited by this paper
• Protection Induced by Plasmodium falciparum MSP142 Is Strain-Specific, Antigen and Adjuvant Dependent, and Correlates with Antibody Responses

  2008cited by this paper
• Suppression of Lethal Plasmodium yoelii Malaria following Protective Immunization Requires Antibody-, IL-4-, and IFN-γ-Dependent Responses Induced by Vaccination and/or Challenge Infection1

  2008cited by this paper
• Heterologous Protein Expression Is Enhanced by Harmonizing the Codon Usage Frequencies of the Target Gene with those of the Expression Host

  2008cited by this paper
• Comparison of Biological Activity of Human Anti-Apical Membrane Antigen-1 Antibodies Induced by Natural Infection and Vaccination1

  2008cited by this paper
• Long-Lasting Protective Immune Response to the 19-Kilodalton Carboxy-Terminal Fragment of Plasmodium yoelii Merozoite Surface Protein 1 in Mice

  2007cited by this paper
• Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum

  2007cited by this paper
• Phase 1 Study of Two Merozoite Surface Protein 1 (MSP142) Vaccines for Plasmodium falciparum Malaria

  2007cited by this paper
• The Importance of Human FcγRI in Mediating Protection to Malaria

  2007cited by this paper
• Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development.

  2007cited by this paper
• Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes.

  2007cited by this paper
• Expression, localization, and erythrocyte binding activity of Plasmodium yoelii merozoite surface protein-8.

  2006cited by this paper
• Safety and Reactogenicity of an MSP-1 Malaria Vaccine Candidate: A Randomized Phase Ib Dose-Escalation Trial in Kenyan Children

  2006cited by this paper
• Safety and Allele-Specific Immunogenicity of a Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Trial

  2006cited by this paper
• Enhanced Protection against Malaria by a Chimeric Merozoite Surface Protein Vaccine

  2006influential reference
• Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.

  2006cited by this paper
• Dimorphic Plasmodium falciparum merozoite surface protein‐1 epitopes turn off memory T cells and interfere with T cell priming

  2006cited by this paper
• Plasmodium falciparum Merozoite Surface Protein 8 Is a Ring-Stage Membrane Protein That Localizes to the Parasitophorous Vacuole of Infected Erythrocytes

  2005cited by this paper
• Process Development and Analysis of Liver-Stage Antigen 1, a Preerythrocyte-Stage Protein-Based Vaccine for Plasmodium falciparum

  2005cited by this paper
• Alteration in Host Cell Tropism Limits the Efficacy of Immunization with a Surface Protein of Malaria Merozoites

  2005cited by this paper
• The Clinical-Grade 42-Kilodalton Fragment of Merozoite Surface Protein 1 of Plasmodium falciparum Strain FVO Expressed in Escherichia coli Protects Aotus nancymai against Challenge with Homologous Erythrocytic-Stage Parasites

  2005cited by this paper
• World malaria report

  2005cited by this paper
• Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response.

  2004cited by this paper
• CpG Oligodeoxynucleotide and Montanide ISA 51 Adjuvant Combination Enhanced the Protective Efficacy of a Subunit Malaria Vaccine

  2004cited by this paper
• Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response

  2004cited by this paper
• CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides.

  2003cited by this paper
• World Health Organization,

  2003cited by this paper
• Biochemical and Immunological Characterization of Bacterially Expressed and Refolded Plasmodium falciparum 42-Kilodalton C-Terminal Merozoite Surface Protein 1

  2003cited by this paper
• The Human Immune Response to Plasmodium falciparum Includes Both Antibodies That Inhibit Merozoite Surface Protein 1 Secondary Processing and Blocking Antibodies

  2002cited by this paper
• Protective Immune Responses to the 42-Kilodalton (kDa) Region of Plasmodium yoelii Merozoite Surface Protein 1 Are Induced by the C-Terminal 19-kDa Region but Not by the Adjacent 33-kDa Region

  2002cited by this paper
• Antibodies against Merozoite Surface Protein (Msp)-119 Are a Major Component of the Invasion-Inhibitory Response in Individuals Immune to Malaria

  2001cited by this paper
• Merozoite surface protein 8 of Plasmodium falciparum contains two epidermal growth factor-like domains.

  2001cited by this paper
• Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum.

  2001cited by this paper
• Linkage of Exogenous T-cell Epitopes to the 19-Kilodalton Region of Plasmodium yoelii Merozoite Surface Protein 1 (MSP119) Can Enhance Protective Immunity against Malaria and Modulate the Immunoglobulin Subclass Response to MSP119

  2000cited by this paper
• A Protective Glycosylphosphatidylinositol-Anchored Membrane Protein of Plasmodium yoelii Trophozoites and Merozoites Contains Two Epidermal Growth Factor-Like Domains

  2000cited by this paper
• Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Secreting Merozoite Surface Protein 1 (MSP1) Induces Protection against Rodent Malaria Parasite Infection Depending on MSP1-stimulated Interferon γ and Parasite-specific Antibodies

  1998cited by this paper
• Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use.

  1997cited by this paper
• Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effect

  1997cited by this paper
• Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds

  1997cited by this paper
• Antibodies that Inhibit Malaria Merozoite Surface Protein–1 Processing and Erythrocyte Invasion Are Blocked by Naturally Acquired Human Antibodies

  1997cited by this paper
• Development

  1996cited by this paper
• Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1

  1996cited by this paper
• Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1.

  1996cited by this paper
• Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection

  1996cited by this paper
• Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1.

  1995cited by this paper
• Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria.

  1995cited by this paper
• Immunogenicity and In Vivo Efficacy of Recombinant Plasmodium falciparum Merozoite Surface Protein-1 in Aotus Monkeys

  1995cited by this paper
• Immunization against malaria with a recombinant protein

  1994cited by this paper
• Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1).

  1993cited by this paper
• Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1.

  1993cited by this paper
• A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth.

  1992cited by this paper
• A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion- inhibiting antibodies

  1990cited by this paper
• A protective monoclonal antibody recognizes a variant-specific epitope in the precursor of the major merozoite surface antigen of the rodent malarial parasite Plasmodium yoelii.

  1989cited by this paper

• An mRNA Vaccine Expressing Blood-Stage Malaria Antigens Induces Complete Protection Against Lethal Plasmodium yoelii

  2025cites this paper
• In vitro evaluation of multi-protein chimeric antigens in effectively clearing the blood stage of Plasmodium falciparum.

  2025cites this paper
• Design and Evaluation of Chimeric Plasmodium falciparum Circumsporozoite Protein-Based Malaria Vaccines

  2024influential citation
• Plasmodium falciparum merozoite surface protein 1 as asexual blood stage malaria vaccine candidate

  2023cites this paper
• Targeting plasmodium α-tubulin-1 to block malaria transmission to mosquitoes

  2023cites this paper
• Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion

  2022cites this paper
• The Cellular and Molecular Interaction Between Erythrocytes and Plasmodium falciparum Merozoites

  2022cites this paper
• Inclusion of an Optimized Plasmodium falciparum Merozoite Surface Protein 2–Based Antigen in a Trivalent, Multistage Malaria Vaccine

  2021cites this paper
• Polymeric particles as a delivery agent for malarial vaccines

  2021cites this paper
• Natural infections with different Plasmodium species induce antibodies reactive to a chimeric Plasmodium vivax recombinant protein

  2020cites this paper
• A Chimeric Plasmodium vivax Merozoite Surface Protein Antibody Recognizes and Blocks Erythrocytic P. cynomolgi Berok Merozoites In Vitro

  2020cites this paper
• Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination

  2020cites this paper
• Prospects for Malaria Vaccines: Pre-Erythrocytic Stages, Blood Stages, and Transmission-Blocking Stages

  2019cites this paper
• The acquisition of long-lived memory B cell responses to merozoite surface protein-8 in individuals with Plasmodium vivax infection

  2019cites this paper
• Immunization with merozoite surface protein 2 fused to a Plasmodium-specific carrier protein elicits strain-specific and strain-transcending, opsonizing antibody

  2019cites this paper
• Development of Blood Stage Malaria Vaccines.

  2019cites this paper
• Malaria transmission assisted by interaction between Plasmodium α-tubulin-1 and Anopheles FREP1 protein

  2019cites this paper
• Genetic diversity of merozoite surface protein-1 C-terminal 42 kDa of Plasmodium falciparum (PfMSP-142) may be greater than previously known in global isolates

  2018cites this paper
• Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant Pfs25, a Leading Transmission-Blocking Vaccine Candidate

  2017influential citation
• Generation and evaluation of a multi-stage multi component malaria vaccine cocktail produced in Nicotiana benthamiana

  2017cites this paper
• Na+ Influx Induced by New Antimalarials Causes Rapid Alterations in the Cholesterol Content and Morphology of Plasmodium falciparum

  2016cites this paper
• Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys

  2016influential citation
• Immunization with Neospora caninum profilin induces limited protection and a regulatory T-cell response in mice.

  2016cites this paper
• Protection against malaria in mice is induced by blood stage–arresting histamine-releasing factor (HRF)–deficient parasites

  2016cites this paper
• Recent advances in recombinant protein-based malaria vaccines

  2015cites this paper
• Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model.

  2014cites this paper
• Survey of bluetongue virus infection in free-ranging wild ruminants in Switzerland

  2013cites this paper